p73 is a p53 homolog that, in vitro, inhibits cell growth and induce apoptosis. In some tumors p73 is monoallelically expressed and this raised the possibility that this gene is subjected to imprinting. Silencing of p73 in acute leukemia and in Burkitt's lymphoma occurs in association with the aberrant methylation of the ®rst exon of the gene. We have analysed the methylation pattern of the p73 promoter and of upstream and downstream sequences in neuroblastoma. Our results demonstrate that p73 expression in this tumor is not regulated by methylation. We concluded that it is unlikely that p73 is imprinted in neuroblastoma and that the methylation-dependent silencing of this gene, thus far, is a characteristic of hematologic malignancies. Oncogene (2000) 19, 4553 ± 4556.
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The p73 gene is a p53 homolog whose overexpression in cultured cells upregulates some p53-responsive genes, promotes apoptosis and inhibits cell growth (Kaghad et al., 1997) . The role of p73 in tumors is still unclear although its unbalanced expression might have profound eects on the biology of cancer cells by in¯uencing apoptotic or dierentiation signaling pathways (reviewed by Kaelin 1999a,b) .
Although p73 is overexpressed in several tumors, its silencing was described in some cases of neuroblastoma, acute lymphoblastic leukemia and Burkitt's lymphoma. Monoallelic expression or the reactivation of a silenced p73 allele were also observed and this raised the possibility that this gene might be subjected to imprinting (Mai et al., 1998a,b; Nomoto et al., 1998; Chi et al., 1999; Corn et al., 1999; Kawano et al., 1999; Ichimiya et al., 1999; Peters et al., 1999; Romani et al., 1999a; Zaika et al., 1999; Scaru et al., 2000) . Genomic imprinting could be of particular importance in neuroblastoma. In fact the preferential loss of maternal alleles at 1p36, in N-Myc single-copy neuroblastoma, suggests that imprinted chromosome 1p genes contribute to the development of this tumor (Caron et al., 1995) . Methylation of 5' cytosine in CpG dinucleotides has been implicated in the maintenance of imprinting and is now considered a key factor in neoplastic and non-neoplastic diseases (for reviews see: Bartolomei and Tilghman, 1997; Baylin et al., 1998; Jones and Laird, 1999) . Silencing of p73 in acute lymphatic leukemia and Burkitt's lymphoma occurs through methylation of the untranslated exon 1 of the gene (Corn et al., 1999; Kawano et al., 1999) . p73 methylation was not observed in a survey of tumor cell lines and in breast, renal and colon cancers (Corn et al., 1999) . However, ®rm conclusions on the role of CpG methylation in the regulation of p73 transcription in these tumors, could not be drawn since the expression pattern of this gene in the samples included in that study was not reported.
To determine if methylation at CpG residues has a role in monoallelic expression or in the silencing of the p73 gene in neuroblastoma, we have analysed the pattern of methylation of the p73 locus in tumors of known p73 transcriptional status.
We have isolated, from a PAC contig (Lo Cunsolo et al., 1998) , plasmid subclones containing the ®rst exon of p73 and the surrounding genomic region. The restriction enzyme map of the 5' end of p73, reported in Figure 1a , indicates that a CpG island, marks the 5' end of p73. Sequencing of the region surrounding exon 1 con®rmed that this DNA segment quali®es as a CpG island (C+G content of 75%; CpG/GpC ratio of 0.83). Multiple transcription factor binding sites were identi®ed by the SIGNAL SCAN software (Prestridge, 1991) (Figure 1b) . Functional studies appeared while this manuscript was in preparation con®rmed that this region acts as a p73 promoter and indicated that an additional CpG island is located further upstream the p73 gene (Ding et al., 1999) .
Promoter prediction by neural network analysis (NNPP) (Reese et al., 1996) identi®ed a putative TATA-box and a CAP signal respectively 66 and 42 nucleotides before the reported beginning of the p73 cDNA sequence. RT ± PCR assays conducted with a forward primer designed from the putative p73 initiator signal and a reverse primer derived from exon 3 demonstrated that p73 transcription begins upstream the site deducted from the published cDNA sequence (Figure 2a) .
A preliminary analysis of neuroblastoma cell lines failed to demonstrate the presence of C m Gs at the 5' end of the gene (Corn et al., 1999 and our data not shown) This is not surprising in view of the high level of p73 expression observed in neuroblastoma cell lines that, in most cases, are monosomic for p73 (Kovalev et al., 1998) .
We have utilized the Methylation-Speci®c-PCR (MSP), the genomic sequencing of bisul®te-modi®ed DNA and the Methylated CpG island ampli®cation (MCA) techniques to assess the methylation status of the p73 gene in 20 neuroblastoma derived from patients at stages I ± IV. MSP is a PCR-based technique that relies upon the bisul®te conversion of unmethylated C into U, leaving the methylated C unmodi®ed. Ampli®cation with primers designed to amplify solely the methylated or the unmethylated target enables the rapid assessment of the methylation status even from minute amounts of tissue samples (Herman et al., 1996) . MCA is a recently developed technique that employs digestion with methylation sensitive (SmaI) and insensitive (XmaI) restriction enzymes followed by ligation of adapters and PCR ampli®cation for the selective enrichment of methylated CpG island (Toyota et al., 1999) . The genomic regions included in the present study are indicated in Figure  1a .
Neuroblastoma tumor samples were kindly provided by Dr Gian Paolo Tonini (IST-Genova) and were collected at onset of the disease according to the LNESG protocol following the institutional guidelines. Tumor-cell content, in all cases, was higher than 85%. The p73 expression status of these samples had been previously evaluated by nested RT ± PCR (Romani et al., 1999a) and was con®rmed by direct RT ± PCR followed by Southern blot analysis of the PCR products (Figure 2b ). Ten tumors did not express p73 and four of them carried a chromosome 1p deletion. Among the informative tumors that expressed p73, mono-and biallelic expression was observed, respectively, in eight and two samples.
We ®rst assayed, by MSP, the methylation status of the promoter and of the ®rst exon of the p73 gene (nt 7257/762; region A and nt +56/+115; region B). As internal controls we utilized the U937 and HL60 cell lines that in a previous study were reported, respectively, as being methylated and unmethylated at the p73 locus (Kawano et al., 1999) . As shown in Figure  2c , the p73 promoter and exon 1, in neuroblastoma, are unmethylated independently from p73 transcription. These results were con®rmed by MCA analysis. In Figure 3b we present the result of the hybridization of a probe that included the p73 promoter and most of exon 1 (nt 7427/+115) to MCA products derived Table 1 . (a) RT ± PCR analysis for the identi®cation of the p73 transcription startpoint. RT ± PCR was conducted with a forward primer designed from the putative p73 initiator signal and a reverse primer from the third exon of the gene. The PCR products were hybridized with a p73-exon2 probe. Below the autoradiography is reported the schematic representation of this PCR reaction. Numbered boxes represent the p73 exons deducted from Kaghad et al. (1997) and from sequence Y11416. The solid line is the additional exon 1 sequence. (b) p73 expression analysis and genotyping of six representative neuroblastoma samples and control cell lines. Primers SN716/ASN938 were utilized for direct p73 RT ± PCR. The ampli®cation products were loaded on a 2% agarose gel, transferred to a nylon membrane and hybridized with a p73 cDNA probe. Genotyping, identi®cation of the expressed allele, cDNA synthesis and RT ± PCR conditions for G3PDH have been described (Romani et al., 1999a) . (c) MSP analysis of representative neuroblastoma samples and control cell lines. MSP was conducted following the protocol described by Herman et al., 1996 . Primers for the Exon 1 reaction reported in this ®gure were those described by Corn et al. (1999) . M and U indicates, respectively, the reaction for methylated or unmethylated sequences. Note that the upstream CpG island (CpG2, region F) is always unmethylated while exon 2 is always methylated Toyota et al. (1999) . Brie¯y DNA was digested sequentially with SmaI and XmaI. Appropriate controls were included to ensure the completeness of the digestion. SmaI cleaves the unmethylated CCCGGG sites leaving blunt ends while XmaI digests the same sequence, even if the internal CpG is methylated, leaving 5'-protruding ends. R-Xma adaptors were linked to the digested DNA and the samples were ampli®ed by PCR utilizing the adaptors as ampli®cation primers. These treatments result in the exponential ampli®cation of DNA fragments included between two closely spaced SmaI sites that were methylated in the starting DNA and thus in the selective enrichment for methylated CpG islands. The presence of speci®c DNA sequences in the MCA amplicons is determined by molecular hybridization. (a) MCA analysis of neuroblastoma samples and control cell lines showing methylation at intron 1 and exons 2 and 4. Probes for the promoter region and for exons 2 and 4 were constructed by PCR (Table  1) . The intron 1 probe derived from Representational Dierence Analysis (RDA) experiments between PAC clones as described (Romani et al. 1999b) . The criteria for probes selection were the absence of repetitive elements and the small size of the recognized fragments to ensure that the target sequences were within the ampli®cation range of the PCR reaction. The positive control for MCA was obtained by digestion of pooled DNA samples directly with XmaI followed by ligation to R adaptors for the ampli®cation of small fragments independently from the methylation status of the SmaI sites. (b) TaqI digestion of the MSP products obtained with the CpG-2 primer set on neuroblastoma and control cell lines. Absence of digestion with the restriction enzyme demonstrates that the three CCGA contained in the unmodi®ed sequence were converted into TTGA and not into TCGA as would have occurred if the CpG dinucleotides were methylated. (c) Genomic bisul®te sequence analysis of the p73 promoter and exon 1. MSP-PCR products from 10 tumor samples and control cell lines were sequenced with a LICOR-4200 automatic sequencing system. Black and white circles represent, respectively, methylated and unmethylated CpG dinucleotides. The presence of a C and a T at the same position in a non-polymorphic CpG was considered as partial methylation and is indicated by gray circles PCR reactions were carried out for 35 cycles (30'' at 948C, 30'' at the annealing temperature, 30'' at 728C). DNA was denatured at 958C for 5' before the addition of the Taq Polymerase. Extension temperature for the CpG-2 unmethylated primer set was 688C. *Indicates the primers utilized by Corn et al. (1999) Methylation of p73 begins in the ®rst intron and does not alter the transcription of the gene. In fact when we analysed, by MSP and MCA, the methylation status of the ®rst intron and of the second and fourth exon of p73 (regions C, D and E) we observed methylation in all the samples independently from the transcription status of the gene (Figures 2c and 3b and data not shown). Aberrant methylation leading to gene inactivation may occur at distant regions; in this respect a good candidate was the second CpG island identi®ed further upstream the transcription startpoint (region F) (Ding et al., 1999) . The MSP analysis reported in Figure 2c , however, indicated that this region is unmethylated also in the U937 cell line where p73 silencing is associated with methylation of the 5' end of the gene. To assess methylation at internal CpG residues of region F we searched for the appearance of new TaqI restriction enzyme sites after bisul®te modi®cation of genomic DNA (Sadri and Hornsby, 1996) . Since newly formed TaqI sites are not present in the ampli®ed fragments it can be safely concluded that also these internal CpGs are unmethylated suggesting that this region does not regulate p73 transcription (Figure 3b) .
Our results indicate that, unlike leukemic cell and cell lines, p73 silencing in neuroblastoma does not involve the aberrant methylation of the gene promoter.
Hypermethylation outside the promoter region may be associated with the loss of transcription (Bartolomei et al., 1993) ; accordingly we have analysed the pattern of methylation downstream and upstream exon 1. Again no correlation between transcription and CpG methylation was observed. These results suggest that p73 is not imprinted in neuroblastoma and that its monoallelic expression does not depend from methylation. Our data suggest also that the critical region for silencing of the p73 gene is within 2 kb from the transcription startpoint. Various experimental evidences suggest that p73 has a speci®c role in lymphoid neoplasms (Kawano et al., 1999; Corn et al., 1999; Scaru et al., 2000) . The observation that distinct mechanisms mediate the epigenetic silencing of p73 in hematological malignancies and in neuroblastoma or probably also in other tumors supports this hypothesis.
